Million-dollar price tags for ultra-rare disease treatments are justified to incentivize drug development

Debate continues over whether million-dollar price tags for ultra-rare disease treatmen....

From the articleFDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease